Production of metallo-[beta]-lactamase (MBL) proteins protects Gram-negative bacteria from almost all [beta]-lactam antibiotics. MBLs hydrolyse [beta]-lactams, abolishing their antimicrobial activity. One method of restoring [beta]-lactam efficacy against MBL producing organisms would be co-administration with an MBL inhibitor, but to date no such inhibitor is commercially available. This project sought to express and characterise a range of MBLs, with the aims of both understanding structure-function relationships within this enzyme family and aiding the identification of MBL inhibitors. VIM-1 is an MBL commonly identified in resistant clinical isolates.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:691255 |
| Date | January 2015 |
| Creators | Salimraj, Ramya |
| Publisher | University of Bristol |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
Page generated in 0.0017 seconds